Life Sciences and Healthcare
Life Sciences
‘Very responsive, knowledgeable, approachable. Always willing to go above and beyond in their service and advice. Always clear in the scope of their instructions.’
Legal 500 2024 – Healthcare and Life Sciences
Our multidisciplinary Life Sciences and Healthcare Group provides solution focused and sector specific commercial advice to leading life sciences and healthcare companies and investors.
Ireland is ideally located to provide access to international markets and many companies see Ireland, not just as a gateway to Europe, but as a base for their international headquarter operations. At Matheson we are at the heart of this vibrant and innovative sector.
Our experience and sector specific knowledge sets us apart within the Irish market, with our team having advised on the leading and most complex M&A transactions, restructuring mandates and regulatory issues within the Irish Life Sciences and Healthcare sector.
Our Service Offering
Corporate Establishment and Expansion Projects
Read More
Corporate Establishment and Expansion Projects
Our Life Sciences and Healthcare Group has a stellar reputation as standing corporate counsel to the vast majority of multinationals in the life sciences sector operating in Ireland, with particular expertise in all aspects of establishment (foreign direct investment) and expansion projects. This includes working with a broad range of life sciences companies, including those involved in manufacturing, R&D, and commercial operations, for example.
Our team provide a coordinated offering in this regard, advising on all aspects of both establishing and expanding in Ireland, including providing advice to our clients from a corporate, regulatory, licensing, real estate, construction, tax and employment perspective.
We have long-standing relationships with our clients operating in the life sciences sector, and advise them on a variety of corporate transactions imperative to their business and ongoing operations.
This includes, for example, advising on ongoing corporate governance matters related to the management of complex organisational structures and product portfolios, advising on the design and implementation of cash repatriation strategies, and advising on ESG matters and the applicability of same.
For more information, visit our Doing Business in Ireland hub.
Led by Emma Doherty, Pat English, Seóna O’Donnellan, Kieran Trant and Gráinne Boyle.

Spin-Offs and Corporate Reorganisation Projects
Read More
Spin-Offs and Corporate Reorganisation Projects
Our Life Sciences and Healthcare Group acts for the vast majority of multinationals operating in the life sciences and healthcare sectors, advising on all aspects of complex spin-off transactions, global reorganisations, and pre and post M&A reorganisation projects.
Our team advise on the following, for example:
- Worldwide reorganisations and restructurings of multinational groups of companies operating in the life sciences sector;
- Spin-off transactions;
- Cross-border and domestic mergers and acquisitions;
- Post-acquisition integration and consolidation projects;
- Rationalisation projects; and
- The overall management of multi-jurisdictional projects related to the above.
Experience Highlights
- Advising a leading US multinational pharmaceutical and medical technologies company on the Irish aspects of the separation and planned spin-off of its consumer health business.
- Advising various multinationals on the Irish legal and tax aspects of significant cross-border repatriation projects.
- Advising a leading US multinational biopharmaceutical company, as its exclusive Irish legal advisor, on a significant post-acquisition reorganisation project following its acquisition of a multinational aesthetics and therapeutics group of companies.
- Advising a leading US multinational pharmaceutical company on the Irish legal and tax aspects of a global IP and commercial restructuring connected with a significant post-acquisition integration project.
- Advising a global medicines company on a significant debt and corporate structure reorganisation.
- Advising a global healthcare company on the Irish legal aspects of a significant multijurisdictional restructuring project related to the spin-off of its renal care business.
- Advising a global biopharmaceutical company on the Irish legal aspects of a significant IP migration project.
- Advising a global medical technologies company on the Irish legal aspects of a significant inbound IP migration and related business restructuring.
- Advising a global biopharmaceutical company on the Irish legal aspects of a significant inbound IP migration project and business reorganisation.
Led by Emma Doherty, Pat English, Seóna O’Donnellan, Kieran Trant and Gráinne Boyle.

Life Sciences M&A Transactions
Read More
Life Sciences M&A Transactions
We are the leading M&A advisors in the Irish life sciences market.
Our team combines our specialist knowledge of the life sciences sector with our market leading M&A practice and are the transactional counsel of choice for internationally focused healthcare and life science companies engaging in M&A transactions in Ireland.
Our team members are not just experts in delivering large and complex M&A transactions for our clients, but also have their fingers on the pulse of the unique risks and challenges that arise in the context of M&A transactions within the sector, such as regulatory approval and oversight, clinical trials and commercialisation matters, IP protection and life cycle management, and pricing and reimbursement.
Our specialised experience helps us to work with our clients to develop and implement creative solutions to navigate risks and maximise value. We have long-standing relationships with our clients operating in the life sciences sector and act for the sector’s market leading multinationals, high growth innovative companies and investment funds.
We act on the most significant transactions within the Irish sector, including advising Horizon Therapeutics plc on all aspects of its approx. $28 billion acquisition by Pillartree Limited (a wholly owned subsidiary of Amgen Inc.), representing the third-largest all-cash transaction in the pharmaceutical sector in history.
Experience Highlights
M&A Transactions
- Advised Horizon Therapeutics plc on all aspects of its $27.8 billion acquisition by Amgen Inc..
- Advised Novo Nordisk on its $1.2 billion acquisition of Prothena Corporation plc’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme.
- Advised STERIS plc on its $3.6 billion acquisition of Cantel Medical Corp.
- Advised Trinity Biotech plc on the restructuring and sale of its “Fitzgerald Industries” life sciences supply business.
- Advised Novo Nordisk on its acquisition of a pharmaceutical manufacturing facility from Alkermes plc.
- Advised Horizon Therapeutics on its acquisition of a pharmaceutical manufacturing facility from EirGen Pharma.
- Advised Astrix Software Technology Inc. on its acquisition of Orbis Lifesciences Consulting Limited.
- Advised BioIQ Inc. and its shareholders on the company’s sale to LetsGetChecked.
- Advised the shareholders of Veritas Genetics Inc. and Veritas Intercontinental, in connection with its sale to LetsGetChecked.
- Advised Verdi I SAS, on its acquisition of Altan Pharma Limited, from Malin Corporation plc.
- Advising on complex collaboration, licensing, and commercial agreements related to the life sciences sector.
- Advised Biocon Biologics Limited on the acquisition and integration of Viatris Inc.’s global Biosimilars business.
Capital Markets Transactions
- Advised Irish registered biotech company ProKidney LP on its successful business combination with Nasdaq listed special purpose acquisition company, Social Capital Suvretta Holdings Corp. III in a deal valuing the combined entity at $2.64 billion. The combined business trades under the ticker symbol “PROK”.
- Advised Trinity Biotech plc, a leading global diagnostic company, on its $45 million strategic investment and partnership with MiCo Ltd, a South Korea-based company listed on KOSDAQ.
- Advised Trinity Biotech plc, a leading global diagnostic company, on all aspects of the refinance of $100 million of exchangeable notes via an issuance of new shares and bank debt.
- Advised Horizon Therapeutics plc on its offering of ordinary shares, which raised net proceeds of approximately $900 million.
- Advised Trinity Biotech plc on a $45m PIPE investment.
- Acted as underwriter counsel and company counsel on a number of IPO projects for medical device and pharmaceutical companies.
Venture Capital / Private Equity
- Advised Impulse Dynamics plc, a fast-growing medical device company, on all aspects of its re-domiciliation from Curacao to Ireland and on subsequent funding rounds, including its recent Series F funding round.
- Advised a consortium of investors, led by Andera Partners SCA, on their investment in Foundry Innovation & Research 1 Ltd (FIRE1), the Irish based designer and developer of remote monitoring devices for the healthcare sector.
- Advised Optum Ventures on its investment in LetsGetChecked, the Irish based software-Medical Technology company.
- Advised Morgan Health, a division of JP Morgan, on its investment in LetsGetChecked.
- Advised Macquarie European Infrastructure Fund 7 on its agreement to acquire the Beacon Hospital Group, one of Ireland’s most technologically advanced private hospitals.
Led by David Fitzgibbon and John Coary

Healthcare M&A Transactions
Read More
Healthcare M&A Transactions
Our market leading M&A team advises on some of the most high profile healthcare transactions in the Irish market.
Our team regularly works with international and domestic operators, as well as private equity, venture capital and infrastructure funds, on their investments into healthcare assets and portfolios, including long term care homes, disability and rehabilitation facilities, private hospitals and other healthcare clinics, as well as veterinary care businesses.
As part of the healthcare transactions we work on, as well as the day to day advice we provide to our clients, our cross departmental team advises across all aspects of our clients’ healthcare businesses, including, but not limited to, construction and real estate, tax, debt finance and competition and regulation.
Our wide ranging sector specific expertise is particularly relevant for clients considering the implementation of consolidation strategies as they enter into and expand within the Irish market, and we have acted for a number of domestic and international clients who have successfully implemented such strategies.
Experience Highlights
- Advised Macquarie European Infrastructure Fund 7 on its acquisition of the Beacon Hospital Group, one of Ireland’s most technologically advanced private hospitals.
- Advised the 101-bed Sports Surgery Clinic, a centre of excellence for joint replacement and surgery for sports soft tissue injuries in Ireland, and its shareholders in connection with the sale of the Sports Surgery Clinic to UPMC, a world-renowned health care provider and insurer.
- Advised Carlyle Cardinal Ireland, a leading Irish provider of alternative investment capital, and the founders of the Sports Surgery Clinic, a centre of excellence for joint replacement and surgery for sports soft tissue injuries, on its sale to international healthcare provider UPMC.
- Advised Orpea (now Emeis) on its acquisition of the TLC Group, the Brindley Group, the First Care group and numerous other nursing homes in Ireland.
- Advised Orpea (now Emeis) on complex competition issues and merger control issues in relation to its various Irish operations and acquisitions.
- Advised a well-known European infrastructure fund on a number of acquisitions of nursing homes in Ireland.
- Advised BC8 on its acquisition of The Talbot Group and on its subsequent sale of The Talbot Group to DIF Capital Partners.
- Acted for an existing shareholder on a series of transactions involving its acquisition of full control of a number of private hospitals and other healthcare facilities in Ireland.
- Advised Sicon on the acquisition of various medical distribution companies to form the Sisk Healthcare Group.
- Advised Bon Secours Mercy Health Inc. in respect of its merger with the Bon Secours hospital group in Ireland.
- Advised the vendor on the sale of Aut Even Hospital to UPMC, Ireland’s oldest private hospital.
- Advised CapVest on its sale of a fund that included CapVest’s investment in the Mater Private Hospital to HarbourVest Partners.
- Advised one of the UK’s largest veterinary care groups on its proposed acquisition of a large portfolio of veterinary practices in Ireland.
Led by George Brady and Rob Barrett,

Regulatory Matters
Read More
Regulatory Matters
Our team advise the world’s leading pharmaceutical, medical device and healthcare services companies on complying with the requirements imposed by various EU and Irish regulators (including for example, the HSE and HPRA) which are of pivotal importance throughout the life cycle of a medicine, medical device or app, or medical service.
This includes advising clients on initial launch and licensing issues across the EU, along with advising on market access, pricing and reimbursement matters. We also advise on ongoing compliance and investigations / audit work, along with carrying out technical advisory work on new frameworks and advising on regulatory aspects of corporate deals and transactions.
Further to this, the team regularly advises on the following from a regulatory perspective:
- Initial launch, licensing, and market access issues;
- Engagement with regulators in relation to pricing rules, reimbursement matters, and access to medicines in Ireland (including potential and actual challenges to HSE decisions);
- The Irish and EU regulatory frameworks including the licensing of drugs, devices, apps and on manufacturing and distribution activities in Ireland;
- Clinical trial regulation and the implementation of trials in Ireland and across the EU;
- Issues arising from regulatory audits of Irish facilities and agreements;
- Legal challenges to decisions by Irish regulators;
- Procurement matters;
- Advertising, social media / influencer and marketing promotions, and online sales by life sciences companies;
- The launch of wearable and app products and services across EMEA, including navigating the Irish and local life sciences and product rules;
- The navigation by e-Prescription and long-distance medicine companies of the Irish and EU regulatory frameworks to facilitate business;
- Pharmaceutical and medical device companies on the regulatory aspects of recent spin-offs of parts of their businesses, including managing regulatory advisors in multiple jurisdictions; and
- Regulatory, antitrust and FDI matters related to life sciences corporate deals and transactions.
Led by Kate McKenna and Rebecca Ryan,

Life Sciences Litigation
Read More
Life Sciences Litigation
Our market leading Disputes and Investigations practice fully understands the complex issues that can arise in the life sciences sector.
Our team offers a broad range of services to our clients, with a particular focus on product liability litigation and medical malpractice litigation from a healthcare litigation perspective. We also advise and act on a broad range of commercial litigation and dispute resolution matters for our life sciences clients.
From a healthcare litigation perspective, we continually act for pharmaceutical companies in cross border issues with many of our clients recognising our leading reputation in the Irish and European market. Our team has acted in landmark cases in Ireland in relation to PIP breast implants, vaginal mesh implants, cardiac devices and vaccination cases.
- Click here for more information on our Healthcare Litigation offering.
- Click here for more information on our Disputes and Investigations offering.
Experience Highlights
- Representing a number of multinational pharmaceutical companies in product liability claims arising from the use of devices and products such as benzodiazepines and the MMR vaccine.
- Acting for a global biopharmaceutical company in the defence of multiple claims related to vaccine litigation.
- Acting for a medical device manufacturer in the defence of multiple claims arising from allegedly defective breast implants.
- Representing a blood product manufacturer in respect of product liability litigation and regulatory hearings.
- Acting for a medical device manufacturer in the defence of multiple claims arising from allegedly defective cardiac devices.
- Advising market leaders in the agricultural sector in recovering for vaccine failure and associated damages.
- Acting for Medical Practitioners in the context of claims involving allegedly defective hip implants used in joint replacement surgery.
- Acting for a manufacturer of vaginal mesh implants in the defence of multiple claims arising from alleged defective products.
Led by Rebecca Ryan, Justine Sayers and Nicola Dunleavy,

IP, Technology and Innovation
Read More
IP, Technology and Innovation
We are market leaders and have a breadth of experience in advising life sciences companies on a range of commercial, intellectual property and data protection related issues often in the context of business critical transactions and functions.
This includes supporting our transactional colleagues on merger and acquisition activity, our regulatory colleagues on compliance work, and advising clients directly on clinical trial agreements, manufacturing and supply arrangements, outsourcing and general compliance advisory work. Our team also regularly advise on collaboration and licensing matters, along with the negotiation and drafting of commercial agreements.
Experience Highlights
- Advising Blackrock Health Group on the negotiation and drafting of outsourcing contracts for hospitals within the group as well as data privacy concerns.
- Advising on the intellectual property and data protection related aspects of Horizon Therapeutics plc’s $27.8 billion acquisition by Amgen Inc, and Novo Nordisk’s $1.2 billion acquisition of Neotope Neuroscience Limited from Prothena Corporation plc, along with advising Trinity Biotech plc on its restructuring and sale of the “Fitzgerald Industries” life sciences supply business.
- Advising several major global pharmaceutical manufacturers on all aspects of data protection and GDPR compliance, including Data Access Requests, and drafting privacy statements and data protection and CCTV policies.
- Advising various pharmaceutical suppliers on the drafting and implementation of service level agreements and supply agreements for use with public hospitals in Ireland.
- Advising Caldera Medical Inc on the purchase of certain assets of Atlantic Therapeutics Limited and in particular the assignment of intellectual property rights in its INNOVO urinary incontinence medical products, along with advising on the negotiation and drafting of a transitional services agreement for implementation following completion.
- Advising a major European plasma products manufacturer on commercial contracts issues relating to logistics and maintenance services within its manufacturing operation.
- Advising Trinity Biotech Plc on a number of distribution agreements and commercial matters.
- Advising Steris in relation to commercial contract review and negotiations.
- Advising Novo Nordisk on intellectual property and CMO contract related issues in the context of its acquisition of certain assets of Alkermes plc.
- Advising a wearable devices supplier on a data protection compliance project relating to its proprietary glucose monitor, including engagement with the Data Protection Commission.
Led by Anne Marie Bohan and Sarah Jayne Hanna,

Environmental, Social and Governance
Read More
Environmental, Social and Governance
We advise a number of multi-national life sciences clients on their energy and infrastructure projects including electricity and gas connections, renewable energy procurement, on-site renewable energy installations, energy efficiency retrofit projects and energy performance contracting.
Our team also advise on sustainability reporting requirements under the Corporate Sustainability Reporting Directive and obligations under the Non-Financial Reporting Directive, Task Force on Climate-related Financial Disclosures and the EU Taxonomy Regulation. This is in addition to advising on corporate governance structures, including reviewing and updating ESG policies and sustainability reporting frameworks.
You can read more of our up-to-date expert insights and thought leadership on our ESG hub.
Led by Garret Farrelly and Susanne McMenamin,

International Tax and Life Sciences
Read More
International Tax and Life Sciences
We advise life sciences companies on all aspects of Irish tax including with respect to complex and high value domestic and international tax controversy matters (ranging from Irish Revenue audits to Mutual Agreement Procedures and Advance Pricing Agreements), the availability of Ireland’s R&D tax credit regime, transfer pricing matters and significant restructuring projects (including recent Pillar Two focused restructurings).
Our indirect tax team also regularly advises life sciences companies on complex Irish VAT and customs duty matters. From a VAT perspective, this includes advising on efficient structuring of supply chains ensuring that available reliefs are appropriately obtained and relied upon (such as Section 56B Authorisations and postponed accounting for import VAT). From a customs perspective, we also advise upon the availability of various reliefs and approvals such as customs warehousing and inward processing and assist clients in obtaining and maintaining such, as well as advising on the classification of products and the appropriate appointment of customs representatives, etc.
Led by Brian Doohan, Catherine O’Meara and Matthew Broadstock.
Click here for more information on our Tax offering.

Experience Highlight
Private investment firm Graham Partners advised on its acquisition of medical device manufacturer Smithstown Light Engineering
Experience Highlight
Shrieve Chemical Company advised on its acquisition of Carbon Chemicals Group Limited
Experience Highlight
ProductLife Limited advised on the acquisition of Elara Pharmaservices
Experience Highlight
Trinity Biotech plc advised on its acquisition of Epicapture Limited
Experience Highlight
Trinity Biotech plc advised on its acquisition of Metabolomic Diagnostics Limited
Experience Highlight
Novo Nordisk advised on its acquisition of its first manufacturing facility in Ireland
News and Insights
View All InsightsCorporate Sustainability Reporting Directive – At a Glance Guide (May 2024)
Read MoreLife Sciences Team

Emma practises corporate law and regularly spends time in the US with her clients. She works with international companies on the establishment, expansion and operation of their businesses in Ireland.
Emma also advises clients on the complex legal issues that can arise on international transactions involving Irish subsidiaries of foreign companies, including advising on a broad range of corporate reorganisations. She regularly leads group-wide multi-jurisdictional international restructuring projects.

Pat English is a Partner in the Corporate Department at Matheson. He is head of the firm’s market-leading International Business Group and co-head of the Firm’s US Business and Inward Investment Groups.
Pat is a highly experienced corporate lawyer focusing primarily on advising overseas clients on establishing operations and doing business in and from Ireland.

Seóna is a partner in the firm’s International Business Group.
Seóna practices Irish corporate law, with a primary focus on advising US and other international clients on the Irish legal aspects of doing business in and from Ireland.

Gráinne Boyle is a partner in the firm’s International Business Group. She practices Irish corporate law, with a primary focus on advising US and other international clients establishing operations, and doing business in and from Ireland.
Gráinne provides advice in relation to inward investment projects, providing insights on the Irish legal considerations associated with establishing operations and headquarters in Ireland.
She also provides ongoing corporate governance advice in connection with the day-to-day operation of Irish businesses. As part of this role, Gráinne acts as an external board advisor, and provides strategic advice on best corporate governance practices.

Kieran Trant is a partner and a member of the US Business and Inward Investment Groups at Matheson.
Kieran practices corporate law and works with international companies on the establishment, expansion and operation of their businesses in Ireland. Kieran also advises clients on the complex legal and commercial issues that can arise on international transactions involving Irish subsidiaries of overseas companies, including advising on a broad range of corporate reorganisations.
As their Irish corporate counsel, Kieran also advises multinational companies on a broad range of corporate governance and general commercial issues, including directors’ duties and compliance matters. In addition, he provides ongoing corporate advice and strategic counselling to clients, including advice in relation to distributions and complex cash repatriation strategies.
Kieran was previously seconded to Matheson’s Palo Alto and San Francisco offices and is a frequent visitor to the San Francisco Bay Area and other US locations where his clients are based.

David is a partner and Co-Head of the Firm’s Corporate Department and Head of the Corporate M&A Group.
He has extensive experience assisting clients across a range of industries on doing business in and from Ireland, including advising on acquisitions/disposals, capital raisings, corporate migrations, cross-border mergers, joint ventures and reorganisations. David has significant experience advising on take-private transactions and has advised on many of Ireland’s most notable transactions.
He has worked with a wide range of domestic and international corporations providing ongoing strategic advice to their boards. He has a broad-based practice reflecting his considerable experience across the agri-food, financial services, healthcare / life sciences and manufacturing sectors.

John is a partner in the Corporate M&A Group and a member of our cross-departmental Healthcare and Life Sciences Group.
John specialises in corporate transactions (both domestic and international) including mergers and acquisitions, shareholder arrangements, equity fundraisings, joint ventures, corporate reorganisations and restructurings, corporate redomiciliations and general commercial matters. He advises leading Irish and multi-national public and private companies on private M&A and public company transactional mandates. John has particular experience in the Life Science and Aviation sectors, having worked on many significant corporate transactions in these sectors in recent years.

David is a partner in the Corporate M&A Group, based in Matheson’s New York office.
David advises on a broad range of public and private company transactions, specialising in equity capital markets deals, public company M&A (hostile and recommended offers), group reorganisations and corporate redomiciliations.
He also advises corporate and individual clients on European securities law, Irish and UK Listing Rules and the Irish Takeover Rules, as well as Irish company law.

Susanne is a partner in Matheson’s Corporate Group specialising in corporate advisory matters and equity capital markets transactions.
Susanne has particular expertise in corporate governance and compliance matters and in securities regulation under the Market Abuse Regulation and the Transparency and Prospectus regimes, the Irish Listing Rules and the Irish Takeover Rules.

Brian is a partner in the firm’s Tax Department and advises multinational corporations doing business in and from Ireland on all aspects of Irish corporate taxation.
Brian has a particular interest in cross border tax planning, transfer pricing and tax controversy matters and also has extensive experience in structuring mergers and acquisitions and corporate reorganisations. His clients include many of the leading multinational corporations operating in the ICT, life sciences, manufacturing, retail and industrial sectors in Ireland. Brian also advises on Irish stamp duty matters particularly in the context of global reorganisations.

Matthew Broadstock is a partner in the Tax practice of Matheson, where he heads the Indirect Taxes group, specialising in cutting-edge VAT developments at both Irish and EU levels as well as advising on Customs and Excise matters, and Relevant Contracts Tax.
Matthew is a member of the Law Society Taxation Committee and is Chair of the Indirect Tax TALC Consultative Committee on behalf of the Law Society during 2025. Matthew plays a pivotal role in shaping Ireland’s indirect tax dialogue with the Revenue Commissioners.

Catherine is a partner in the tax department at Matheson.
Catherine has significant experience advising multinational corporations doing business in Ireland on Irish corporate tax.
Her work primarily comprises advising multinationals on the Irish tax aspects of their operations including tax effective structuring of global reorganisations, IP ownership, inward investment projects and cash repatriation strategies.

Anne-Marie is a partner and Head of the Technology and Innovation Group at Matheson.
Anne-Marie Bohan has extensive experience in technology related legal matters, gained over nearly three decades with Matheson, and is Head of Matheson’s Technology and Innovation Group. Anne-Marie is widely recognised for her skill in bringing together significant practical experience in advising on technology and privacy legal issues with industry knowledge and an understanding of applicable regulatory rules and regulatory requirements.
Anne-Marie is recognised by The Legal 500 as a Leading Partner for both Information Technology and Fintech, and is in The Legal 500 Data Privacy and Data Protection Hall of Fame.

Kate is a partner in the Competition and Regulation Group.
Prior to joining Matheson, Kate worked at a Magic Circle law firm in London.
Kate’s competition practice involves advising clients on merger control, behavioural competition issues (including investigations of alleged collusion and abuse of dominance), State aid, the Foreign Subsidies Regulation, Foreign Investment Screening regimes & public procurement competition issues.

Nicola Dunleavy is “not only a skilled lawyer but also has strong emotional intelligence”.
Nicola Dunleavy is a partner in Matheson’s Disputes and Investigations Group, with a broad commercial litigation, investigations and arbitration practice. In 2021 she was appointed by the Irish Government as a Senior Counsel.
Nicola is represents clients in complex, multi-jurisdictional commercial disputes, including arising from mergers and acquisitions and EU law, and in constitutional litigation. Sectors include technology and telecommunications, pharmaceutical, chemicals, food and drink, waste, water, energy, mining, and transport.

Rebecca Ryan is a partner and head of the Healthcare Group in Matheson’s Disputes and Investigations Group and a recognised leader in her field, specialising in professional indemnity and product liability claims.

Justine Sayers is a partner in the Healthcare Group, specialising in professional indemnity claims (in particular, medical negligence and clinical malpractice), healthcare, catastrophic personal injuries claims and product liability actions.

Garret is a partner and head of both Matheson’s Energy, Natural Resources and Utilities Group and Projects and Infrastructure Group. Garret is also a member of Matheson’s ESG Advisory Group.
He advises on all aspects of energy, natural resources, utilities and infrastructure projects and project financing, from PPPs to privately-financed electricity and gas developments and privatisations as well as electricity, gas and telecommunications network infrastructure.
Garret specialises in particular in the areas of electricity and gas market regulation and trading.

Sarah Jayne Hanna is a partner in Matheson’s Technology and Innovation Group.
Sarah Jayne advises a wide range of clients on technology issues, with a particular focus on digital services regulation (DMA and DSA), cybersecurity, technology and commercial contracts, intellectual property, data protection and privacy.

Simon is a partner in the Competition and Regulation Group at Matheson.
Simon advises on all aspects of EU and Irish competition and regulatory law with a particular focus on regulated sectors primarily the telecoms, media, technology, infrastructure, food & beverage and life sciences sectors.
Simon also co-leads Matheson’s Foreign Direct Investment / Foreign Investment Review practice advising businesses on navigating Ireland’s new FDI regime and acquisitions of ‘critical’ and ‘sensitive’ assets and businesses.






















